These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8823354)

  • 1. Pharmacoeconomics of antipsychotic drug therapy.
    Hargreaves WA; Shumway M
    J Clin Psychiatry; 1996; 57 Suppl 9():66-76. PubMed ID: 8823354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Looking beyond the formulary budget in cost-benefit analysis.
    Cohen LJ
    Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.
    Revicki DA
    J Clin Psychiatry; 1999; 60 Suppl 1():7-11; discussion 28-30. PubMed ID: 10037164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacoeconomics of clozapine: a review.
    Meltzer HY; Cola PA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
    Revicki DA
    Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.
    Finley PR; Sommer BR; Corbitt JL; Brunson GH; Lum BL
    Psychopharmacol Bull; 1998; 34(1):75-81. PubMed ID: 9564202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of psychosis: resetting the drug cost 'thermostat'.
    Reid WH
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():166-8. PubMed ID: 7961565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulary decisions and health economics.
    Glazer WM
    J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
    Luchins DJ
    Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine for refractory schizophrenia: the Illinois experience.
    Buckman RW; Malan RD
    J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.